Q-omics provides the consensus-scored CCDC120 profile across patient tissues and cancer cell-line models. CCDC120 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CCDC120 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, CCDC120 RNA expression shows 19,774 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, COAD, and THYM as cancer lineages where CCDC120 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC120 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC120 survival associations across molecular data types. CCDC120 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC120 RNA expression–survival associations across cancer types. High CCDC120 expression shows unfavorable associations in LIHC, SKCM, LUAD and KIRP, but favorable associations in THYM and MESO. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CCDC120 RNA expression.
This table summarizes CCDC120 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC120. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC120 shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, LIHC, LUSC and LUAD. The COAD box plot shows higher CCDC120 RNA expression in tumor versus normal tissue (log2 FC = +1.061, t-test p < 0.001).
This table shows molecular features associated with CCDC120 in patient tissues and cancer cell lines. In patient samples, CCDC120 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC120 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
